Key result
TRIM family proteins modulate inflammation and fibrosis in chronic lung diseases, emerging as potential therapeutic targets.
Why the study?
While TRIM proteins are extensively studied in lung tumors, their roles in non-tumor chronic lung diseases remain underexplored.
TRIM proteins play a pivotal role in the pathogenesis of non-tumor chronic lung diseases and represent promising but challenging therapeutic targets.
Remains hypothesis-generating for new targets in chronic lung disease; leaves open prospective validation before any practice change.
While TRIM proteins are extensively studied in the context of lung tumors, their roles in non-tumor chronic lung diseases remain underexplored. This review delves into the emerging significance of TRIM family proteins in the pathogenesis of idiopathic pulmonary fibrosis (IPF), asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension (PH). TRIM proteins modulate key pathological processes, including inflammation, fibrosis, and cellular remodeling, contributing to disease progression. We highlight their potential as biomarkers and therapeutic targets, offering promising avenues for drug development in these debilitating respiratory disorders. However, the translation of these findings into clinical applications faces significant challenges. These include the dual functional nature of TRIM proteins, their context-dependent roles, the complexity of their downstream signaling networks, and the limitations of current therapeutic strategies in achieving tissue-specific targeting with minimal off-target effects. Addressing these challenges will require innovative approaches and interdisciplinary efforts to unlock the therapeutic potential of TRIM proteins in non-tumor chronic lung diseases.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) conducted a review in Chronic non-tumor lung diseases (IPF, asthma, COPD, PH). TRIM proteins was evaluated. TRIM family proteins modulate inflammation, fibrosis, and cellular remodeling in chronic non-tumor lung diseases, offering potential as biomarkers and therapeutic targets despite translational hurdles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: